Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement

Francesco Giotta, Agnese Latorre, Antonio Cramarossa, Giovanni Simone, Carlo Florio, Stefano Oliva, Vito Lorusso

Research output: Contribution to journalArticlepeer-review


We present the case of a 58-year-old woman with breast cancer metastasizing to the liver after adjuvant chemotherapy. A liver biopsy confirmed metastatic lesions from breast cancer that were immunohistochemically positive for estrogen/progesterone receptors and HER2. After first-line treatment with trastuzumab and vinorelbine, the patient commenced therapy with capecitabine (1000 mg/m2 twice daily, days 1-14) and lapatinib (1250 mg/day). Three months after the administration of this combination therapy, the liver metastases had shrunk substantially. Lapatinib may have the potential to convert trastuzumab-refractory tumors to trastuzumab-sensitive tumors in HER2-positive breast cancer by upregulation of the cell surface expression of HER2. Further study will be needed to evaluate in the clinic the combination of lapatinib and an m-TOR inhibitor as a treatment approach in HER2 overexpressing breast cancer that shows a poor response to trastuzumab. Copyright - Il Pensiero Scientifico Editore.

Original languageEnglish
Issue number6
Publication statusPublished - Nov 2013


  • HER2-positive metastatic breast cancer
  • Lapatinib
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement'. Together they form a unique fingerprint.

Cite this